Panitumumab - intravenous

Patient Medicine Information
Why do I need this medicine?
Panitumumab is used on its own or together with other medicines to treat cancer of the bowel with a certain type of tumour known as a wild-type RAS tumour.
How do I use this medicine?
Panitumumab is to be given intravenously (into the vein) via a drip. It is delivered directly into the bloodstream via the blood vessel.

Your doctor or nurse will administer this medicine for you.

The dose of Panitumumab will be decided by your doctor. Your doctor will advise you on the treatment timeframe depending on the severity of your condition, effectiveness of therapy and your tolerability to this medicine.
What should I do if I have forgotten to use this medicine?
Ensure that you keep all appointments with your doctor so that you do not miss any doses. Your doctor also needs to regularly monitor your response to Panitumumab.

If you miss an appointment or miss an injection, alert your doctor or nurse. A replacement appointment or injection should be given as soon as possible.
When should I not use this medicine?
Alert your doctor if you have the following conditions:
  • interstitial pneumonitis (swelling of the lungs marked by cough and shortness of breath)
  • pulmonary fibrosis (scarring and thickening of the lungs)
as this medicine may not be suitable for you.

Alert your doctor if you are pregnant or planning to have a baby soon. If you become pregnant while on Panitumumab, alert your doctor immediately. This medicine may cause harm to your unborn child. Use proven birth control methods while being treated with Panitumumab and for at least 2 months after discontinuing therapy. You may wish to discuss birth control methods with your doctor.

Do not breastfeed while you are being treated with this medicine and for at least 2 months after discontinuing therapy.

Do not use Panitumumab with oxaliplatin (medicine for cancer), if you have mutant RAS tumour or if your RAS tumour status is unknown.

This medicine is not indicated to be used with bevacizumab (medicine for cancer) plus treatment regimen (containing either oxaliplatin or irinotecan and fluorouracil).
What should I take note of while using this medicine?
Inform your doctor if you have or have had the following conditions:
  • severe dryness of the eye
  • keratitis (inflammation of the cornea of the eye)
  • risk of keratitis (inflammation of the cornea of the eye) or severe dryness of the eye e.g. wearing contact lenses
If you are going for a radiation therapy, inform your doctor that you are using this medicine.

Keep your appointments with your doctor. Your doctor needs to monitor your condition and your response to Panitumumab regularly.
  • Before initiating treatment, your doctor needs to test whether or not your tumours are classified as wild-type RAS.
  • Your doctor will need to regularly monitor your body’s electrolytes (minerals found in the body), especially calcium and magnesium levels.
What side effects could I experience?
Panitumumab may cause dizziness or visual disturbances (e.g. new growth of eyelashes, swollen eyelid; redness, itchiness, dryness or irritation of the eye). If affected, do not drive or take part in any activity in which you need to be alert or to see clearly.

Other side effects may include any of the following: tiredness, nausea, diarrhoea, vomiting, stomach pain, constipation, weight loss, difficulty sleeping, back pain, cough, swelling in the limbs, fever, hair loss, acne or rash resembling acne, redness, itching, drying, and flaking of the skin.

This medicine may also increase your sensitivity to sunlight. Apply sunscreen when going outdoors and avoid direct or prolonged exposure to sunlight and UV lamps.

Some side effects may need immediate medical help. Alert your doctor quickly if you experience any of the following:
  • severe diarrhoea
  • worsening redness, itchiness, dryness, cracking or flaking of the skin; severe pimple breakouts, formation of severe local abscesses (formation of pus possibly due to bacterial infection)
  • severe blistering of the skin, mouth, eyes or genitals
  • persistent cough, wheezing, difficulty breathing
  • blurry vision; worsening redness, itchiness, dryness, irritation or pain of the eye; excessive watering of the eye, sensitivity of the eye to light
  • hives, swelling of the face, chest pain or tightness, palpitation, difficulty swallowing
Inform your doctor if any of these side effects do not go away or are severe, or if you experience other side effects.
Can I use this with other medicines?
Do not use Panitumumab with oxaliplatin (medicine for cancer), if you have mutant RAS tumour or if your RAS tumour status is unknown.

This medicine is not indicated to be used with bevacizumab (medicine for cancer) plus treatment regimen (containing either oxaliplatin or irinotecan and fluorouracil).

Always notify your doctor and pharmacist if you are taking any other medicines, including herbal tonics such as traditional Chinese medicines, supplements and medicines that you buy without a prescription.
What special dietary instructions should I follow?
Avoid alcohol.
How should I store this medicine?
Store in the refrigerator, between 2-8°C. Do not allow to freeze. If frozen, this medicine will become ineffective and should not be used. Protect from light.

Medicines must not be used past the expiry date.
This information is independently developed by MIMS based on panitumumab - intravenous and is provided for your reference only. It is not a replacement for and should only be used in conjunction with full consultation with a licensed healthcare professional, the information provided by your pharmacist and/or the manufacturer of the medication. It may not contain all the available information you require and cannot substitute professional medical care, nor does it take into account all individual circumstances. Although great effort has been made to ensure content accuracy, we shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in